#roadmap to gilead

[tomorrowusa]

Two state legislators who gave high profile speeches at the Democratic National Convention tell MSNBC why the MAGA Project 2025 was the subject of their presentations last week.

A couple of nicknames I have for Project 2025 are Mein Trumpf and Roadmap to Gilead. This is not a document that is compatible with American democracy.

Trump lies outright by claiming he has no connection to Project 2025. A Trump cabinet member, Russ Vought, is one of the main cheerleaders and propagandists for Project 2025. Vought recently told British investigative reporters that people should ignore Weird Donald's feigned ignorance of the project.

This is a partial list of Project 2025 authors.

If Trump truthfully claims not to know dozens of members of his own administration then that's a clear indicator of his deep dementia. 🤤

The legislators who spoke to MSNBC are Michigan State Sen. Mallory McMorrow (D-08) and Pennsylvania State Rep. Malcolm Kenyatta (D-181). They are the sort of people we need in our state governments.

If you'd like to help elect Democrats to your state legislative bodies, first find out which districts you're in and who represents you. This site helps with that.

Find Your Legislators Look your legislators up by address or use your current location.

Once you know which districts you're in, contact your county or state Democratic Party organization and ask how you can help elect (or re-elect) Democrats to the legislature from your districts.

Volunteering to help with legislative campaigns will actually bring you in contact with the candidates themselves from time to time. It's very grassroots and personal. Remember that Barack Obama and Jimmy Carter were members of their respective legislatures at one time.

[waywardunknowntheorist]

Liposome Drug Delivery Market Analysis by Opportunities, Emerging Technologies, Future Plans and Growth Rate To 2031

The market research study titled “Liposome Drug Delivery Market Share, Trends, and Outlook | 2031,” guides organizations on market economics by identifying current Liposome Drug Delivery market size, total market share, and revenue potential. This further includes projections on future market size and share in the estimated period. The company needs to comprehend its clientele and the demand it creates to focus on a smaller selection of items. Through this chapter, market size assists businesses in estimating demand in specific marketplaces and comprehending projected patterns for the future.

The Liposome Drug Delivery market report also provides in-depth insights into major industry players and their strategies because we understand how important it is to remain ahead of the curve. Companies may utilize the objective insights provided by this market research to identify their strengths and limitations. Companies that can capitalize on the fresh perspective gained from competition analysis are more likely to have an edge in moving forward.

With this comprehensive research roadmap, entrepreneurs and stakeholders can make informed decisions and venture into a successful business. This research further reveals strategies to help companies grow in the Liposome Drug Delivery market.

Market Analysis and Forecast

This chapter evaluates several factors that impact on business. The economics of scale described based on market size, growth rate, and CAGR are coupled with future projections of the Liposome Drug Delivery market. This chapter is further essential to analyze drivers of demand and restraints ahead of market participants. Understanding Liposome Drug Delivery market trends helps companies to manage their products and position themselves in the market gap.

This section offers business environment analysis based on different models. Streamlining revenues and success is crucial for businesses to remain competitive in the Liposome Drug Delivery market. Companies can revise their unique selling points and map the economic, environmental, and regulatory aspects.

Report Attributes

Details

Segmental Coverage

Product

Liposomal Doxorubicin

Liposomal Paclitaxel

Liposomal Amphotericin B

Others

Technology

Stealth Liposome Technology

Non-PEGylated Liposome Technology

DepoFoam Liposome Technology

Lysolipid Thermally Sensitive Liposome (LTSL)

Application

Fungal Diseases

Cancer Therapy

Pain Management

Viral Vaccines

Photodynamic Therapy

Regional and Country Coverage

North America (US, Canada, Mexico)

Europe (UK, Germany, France, Russia, Italy, Rest of Europe)

Asia Pacific (China, India, Japan, Australia, Rest of APAC)

South / South & Central America (Brazil, Argentina, Rest of South/South & Central America)

Middle East & Africa (South Africa, Saudi Arabia, UAE, Rest of MEA)

Market Leaders and Key Company Profiles

Takeda Pharmaceutical Company Limited

Novartis AG

Luye Pharma Group

Ipsen Pharma

CELSION, Inc.

Gilead Sciences, Inc.

Astellas Pharma, Inc.

Johnson & Johnson Services, Inc.

Acrotech Biopharma, Inc.

Pacira Biosciences, Inc.

Other key companies 

Our Unique Research Methods at The Insight Partners

We offer syndicated market research solutions and consultation services that provide complete coverage of global markets. This report includes a snapshot of global and regional insights. We pay attention to business growth and partner preferences, that why we offer customization on all our reports to meet individual scope and regional requirements.

Our team of researchers utilizes exhaustive primary research and secondary methods to gather precise and reliable information. Our analysts cross-verify facts to ensure validity. We are committed to offering actionable insights based on our vast research databases.

Strategic Recommendations

Strategic planning is crucial for business success. This section offers strategic recommendations needed for businesses and investors. Forward forward-focused vision of a business is what makes it through thick and thin. Knowing business environment factors helps companies in making strategic moves at the right time in the right direction.

Summary:

Liposome Drug Delivery Market Forecast and Growth by Revenue | 2031

Market Dynamics – Leading trends, growth drivers, restraints, and investment opportunities

Market Segmentation – A detailed analysis by product, types, end-user, applications, segments, and geography

Competitive Landscape – Top key players and other prominent vendors

About Us:

The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us: www.theinsightpartners.com

[serenagaywaterford]

It’s aggravating to see aunt Lydia get some sort of redemption arc both in the new book (Why, Margaret?!), and possibly in season 4. She should be the last person to get it, as far as I am concerned. She is a real believer, the only one who’s totally devoted to Gilead, 100%. Not even Fred, or other commanders, and certainly not Serena. Yet, people scream bloody murder if there is even a hint of Serena turning to the good side. But they want it for aunt Lydia, fuck’em!

RIGHT?!

Without going into how bad a book The Testaments is (cos, lbr, it isn’t a good novel), I was just SO disappointed that even Atwood went that route. I mean, it was a bit obvious that Miller wanted to soften Lydia and that absolutely atrocious, nonsensical, bullshit S3 episode was proof of that (and what an insult to Ann Dowd tbh. She deserved so much better).

I literally cannot buy any of the “Aunt Lydia isn’t THAT bad! She’s not like Serena! She just a true believer!”

And...???

I don’t see how she’s not worse than Serena? The only thing people seem to think about is 2x10. 

“Well, Aunt Lydia didn’t help Fred pregnancy-rape June!” 

No, she didn’t. That’s right.

She just chained her up in a basement, force fed her, and threatened her with death over and over and over until she completely broke her psychologically and made her into a walking zombie-womb to serve her One True Purpose -- to such a degree that even Serena (Serena! The one who wanted a perfect obedient Handmaid!) is like, “WTF?! This is too much, yo. Where my snarky baby factory at?” 

She beat and maimed other women in front of June as payback because she knew she couldn’t touch her. (Hmm, familiar? Except Serena slapped Rita. Aunt Lydia literally burned Alma’s arm over open flame.)

She took Janine’s EYE for merely talking back(!), and Lilly’s TONGUE, and attempted to get the Handmaid’s to murder Janine themselves. She’s had June’s feet lashed so hard she can’t walk--MULTIPLE TIMES. And those are only the abuses we know about. But, no, she didn’t help any husband rape June, that’s true. 

“UWU LYDIA! She’d never suggest such a thing like Serena did!” 

No, she wouldn’t but not because she cares about JUNE lolololol; she cares about the BABY and it is a terrible idea medically for a healthy birth (which is incidentally why I don’t buy that whole 2x10 episode. Serena’s disgusting and furious but she’s not fucking stupid.) That is all Lydia is concerned about. That is her validation and her raison d’etre; if she doesn’t produce obedient Handmaids that give men healthy babies, she’s failed. And I don’t believe that it’s entirely fear that motivates her. She seems to get a very clear sort of power trip and glee from exercising such brutality on young women. Hence, her attitude and acceptance towards how the system treated Natalie. Babies above all! Fuck women, they’re literally just machines. They are BROOD MARES.

“Aunt Lydia didn’t hold June down to be raped every month!”

No, she didn’t. That’s right.

She just trained 100s or 1000s of girls with brutal torture to lie down and take it. She fully supports the Ceremony. Fully. 100%. Even horrible Serena hates it and VISIBLY is uncomfortable with it (but she’s a selfish, delusional coward with anger & jealousy issues so she abides it).

Absolutely everything else Serena has done, short of writing an anti-feminist book and making speeches pre-Gilead, Aunt Lydia has also done. Randomly beat June? Check. Lock June in a room? Check. Scream at June? Check. Uphold the ideals of Gilead? Check. Aunt Lydia ACTIVELY abused, tortured, maimed, bullied, and straight up murdered numerous women. Not just one or two. How many Handmaids has she “trained”? COUNTLESS. Without a hint of remorse. Sometimes she has a soft spot for Janine, or very occasionally, June, but mostly she seems to just treat them as her troublesome pets. Like cattle--to the point of literally using a cattle prod on disobedient ones. A farmer can care about his cattle but it doesn’t make him not a farmer.

Hell, there’s that episode in S1 where Lydia is beating/electrocuting the shit out of June for talking back and Serena swoops in to stop the assault. (Her motives are shitty, and she snaps back to own horrid self not long after, but still...)

Yeah, considering they’re reworking S4 to be more in line with The Testaments is just... sad. Not that we didn’t see them attempting to woobiefy Lydia in S3 already, but I will guess S4 will see her suddenly and randomly taking Handmaids’ concerns seriously. HOW OOC IS THAT? Like, there’s been NO emotional journey for Lydia. It’s why her behaviour in 3x06 didn’t make sense to me. She goes from savagely assaulting Janine in 3x04 to “Oooh, June! This muzzle is so sad! Alexa, play Despacito!” I didn’t buy ANY of Lydia’s randomly swerving and flaky narrative in S3. I have no problem with her expressing her humanity and the audience seeing reasons to sympathize with her (like 2x08) but it was SO ALL OVER THE PLACE in S3 that I can only shudder and how they’re going to do S4. Especially using The Testaments as a roadmap... like suddenly Lydia is a resistance fighter?

Give me a fucking break.

And I think the problem I have with giving Lydia the so-called “redemption arc” on THT is that...

I don’t care.

Who really does?

Lydia is at best a secondary character who has had zero to little development. She’s literally had one (terrible) background episode that was shitty and full of sexist tropes, that only went to show what a snivelling, vengeful, crazy religious bigot she is--and that’s supposed to set her up for THT Redemption™? Suddenly she’s going to switch sides, just like that? Because White Saviour June has spoken to her? (Again, don’t get me started on the sheer idiocy of June (the woman (directly/indirectly) responsible for multiple women DYING in S3 alone) being touted as some precious saviour of women on Jesus-like levels.) Aunt Lydia is magically going to see the light of her wrongdoing?

PLEASE.

And meanwhile, they had a female character who is also a monster on about the same level--just in a different way, who is arguably a lead character and has had PLENTY of background and development, and even started--a few times--down a path that could slowly and ORGANICALLY lead her to remorse and change, and ultimately something vaguely like a redemption arc... but nope! LMAO. PSYCHE!!! Too easy, I guess? Too predictable? 

Yes, because I watch THT to be shocked by the unpredictable... /sarcasm. C’mon.

Why bother giving Serena ANY sort of development just to do her so dirty like S3 did, and switch it up so she stays repulsive but AUNT LYDIA MAGICALLY and OUT OF NOWHERE suddenly changes all her long-held and incredibly cemented beliefs? Meanwhile we’ve seen Serena wavering in hers THE ENTIRE SERIES. We’ve seen her try to break the system, to fight against it. Weakly, and she’s a sissy, but hey, it’s SOMETHING. More than we ever saw with Lydia.

No, giving Janine a nicer eyepatch after YOU RIPPED HER EYEBALL OUT FOR TALKING BACK is NOT the same as Serena standing up in front of a council of men and reading in order to give all females the chance to read. Giving Janine a piece of cake for not making a scene at a gala is NOT the same as Serena giving “her” baby away to make sure she has a better life outside the hellscape that she knows is Gilead. What Aunt Lydia has done for “her girls” pales completely with what very little Serena has done for both June, Nichole, and women (/herself lol).

It’s like saying Fred deserves redemption because he let the Handmaids have devilled eggs in 3x04. Or gave June a photo of Hannah. (Which incidentally, Atwood wrote Serena giving that to June. So, let’s just keep taking things away from Serena, Miller. Good job.)

I just......

I...

No.

Aunt Lydia deserves a redemption arc as much as Fred Waterford does. But even Fred--yes, even Fred--has more substantial character development to sustain such a story, and a shift in his arc. Well, I should say nobody “deserves” a redemption arc. But rather, it makes SENSE for a particular character to experience one.

Honestly, I just don’t understand the flagrant Serena hate when people like Fred and Lydia exist. I don’t see why it makes more sense and is less offensive for either of those monsters to get this mythical redemption arc over Serena, the second most developed character in the entire series.

“We need a foil for June! We need her to have a villain to fight against!” 

Yes, I agree, dipshit, it’s called Gilead. It’s called female oppression. It’s called the inherent rampant violent misogyny there, and even in “normal” society. It’s the stealing of children. It’s every man in any position of power. It’s religious and ideological extremism. It’s the commodification of women’s bodies as machines for baby-making and male sexual gratification. It’s the Sons of Jacob. It’s international governmental complacency. It’s war.

THERE ARE SO MANY EVIL, VILLAINOUS THINGS IN THT. Serena does personify some of these things, sure. So do ALL the other characters everyone is less upset about getting redemption arcs. But Serena doesn’t need to be the be-all of all these things. She doesn’t have to be the visceral manifestation of all those things forever.

Okay, I just have to stop here cos I can go on forever. 

To me, it’s only makes narrative sense for Serena--and ONLY Serena--to get this highly-prized yet still completely imaginary THT Redemption Arc™. And that’s my controversial opinion lol.

[newsupdate-1]

Biotechnology Market To Observe Exponential Growth In Near Future

The most recent analysis on the Biotechnology market provides a comprehensive review of all the important factors expected to drive market growth, including major drivers, constraints, market share, industry volume, recent trends, major breakthroughs, emerging opportunities, and future scope. The report's most crucial outcome for new market entrants includes a market-specific study, successful working strategies, key developments in the industrial sector, and major activities of leading players to persist in the market. This comprehensive research report includes a full market analysis as well as a market expert's opinion from the standpoint of the current market position and future projections.

Growing hepatitis B disease, increasing interest in horticultural items such as sugarcane, rice, beans, and wheat due to the increasing populations in economies such as the U.S., China, and India are expected to push the overall biotechnology market.

Get Sample Copy of This Research Report: https://www.polarismarketresearch.com/industry-analysis/biotechnology-market/request-for-sample

Competitive Landscape of Biotechnology Market

The prominent players present in the market are: (Abbott Laboratories, Agilent Technologies, Amgen, BioGen Medical Instruments, Bio-Rad Laboratories, Danaher, F. Hoffmann-La Roche, Illumina, Merck, PerkinElmer, Qiagen, Thermo Fisher Scientific, Gilead, Celgene, Novo Nordisk A/S, Novartis AG, Sanofi Aventis, and Lonza).

Market Segmentation

The study divides the Biotechnology market into several parts to make it easier to understand the market dynamics. The major shareholder, higher revenue-generating, and dominating segments that are major drivers for the growth of the target market are covered in this section of the report. Players will need such analysis to determine the actual scope of the futuristic outlook and the potential for increased revenue.

COVID-19 Impact Analysis

With detailed research, the research report discusses the influence of the COVID-19 pandemic on the Biotechnology market growth. This study will serve as an ideal roadmap for market players to devise strategies to overcome the negative effects of COVID-19 and seize the market's current prospects. This section is included in the report to give market readers a clear picture of the market environment throughout the pandemic period, as well as estimates for the post-pandemic condition. All readers, as well as stakeholders, vendors, and purchasers, will obtain a thorough grasp of the market on a domestic and worldwide level as a result of this in-depth market analysis.

Regional Analysis

North American pharma and biotech organizations have experienced excellent success in the last couple of years resulting in a larger revenue share. Universities and research institutes are also introducing various biotech-based programs which would help the industry to gain much-required traction.

The Asia Pacific industry on the other hand is anticipated to grow at the most significant rate due to improving and growing healthcare infrastructure coupled with local companies in this region focusing on developing advanced medicines to cure chronic diseases such as cancer with the help of biotechnology. Strong government and federal assistance and recruitment of extremely trained researchers have made it possible for countries such as China and India to swiftly develop capacity for regenerative medication.

Access Full Report: https://www.polarismarketresearch.com/industry-analysis/biotechnology-market

Reasons to Purchase this Report

·         Analysis at the domestic and country-level that sheds light on the demand and supply aspects that are largely driving the Biotechnology market's growth.

·         A competitive landscape that includes firm profiles with essential financial data, a SWOT analysis, product offerings, recent developments, and strategies used.

·         Comprehensive market analysis, including key drivers, restraints, growth rate, current trends, and potential prospects.

·         Market segmentation analysis, which includes both quantitative and qualitative research, as well as the impact of policy and economic factors.

Customization of the Report

The report on the target market can be customized as per your specific requirements to fulfill the desired goals. Please get in touch with our team to get access to the most authentic report on the market. https://www.polarismarketresearch.com/industry-analysis/biotechnology-market/request-for-customization

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[ravidbmr]

Cystic Fibrosis Market Sales and Profit Forecast Analyzed in a New Research Study to 2028

The Cystic Fibrosis Market report can extract and offer in-depth analysis and comprehensive in-sights about the industry. These insights indicate how it is or it will affect the complete growth and future trends of market. Apart from this, the report covers different growth factors such as Cystic Fibrosis market driving factors, challenges, restraints, upcoming opportunities and existing market trends, which are helping the market to expand globally.

An all-inclusive Cystic Fibrosis market report conducts thorough competitive research to supply better market insights. This market report performs comprehensive study about Cystic Fibrosis industry and tells about the market status within the forecast period. The business report explains the moves of top market players and makes that range from mergers, joint ventures, trending innovation and business policies, developments, products launches, acquisitions. This Market research examines various segments which aids for the quickest development amid the estimated forecast frame. Geographical areas like North America, South America, Europe, Asia-Pacific and Middle East & Africa also are considered for the Market research.

Get Free Sample Report Including Detailed Analysis@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-cystic-fibrosis-market

It gives a detailed overview of the market, current trends, future 8 YEAR roadmap, Market challenges, industry environment, and also describes the industry chain structure & opportunities in the current market. This report Provides in-depth analysis of the scope of current and future market including the major factors such as Revenue forecast, company share, competitive landscape, growth factors, and trends, SWOT analysis i.e., Strength, Weakness, Opportunities, and Threat to the industry.

Key Market Competitors: The major players covered in the cystic fibrosis market report are AbbVie Inc, Allergan, Chiesi Farmaceutici SpA, F. Hoffmann-La Roche Ltd, Gilead Sciences, Novartis AG, Pharmaxis Ltd, Alaxia, Alcresta Therapeutics, Inc, AstraZeneca, Genentech, Inc.

The Cystic Fibrosis Market report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Cystic Fibrosis market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyses the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Cystic Fibrosis market.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/toc/?dbmr=global-cystic-fibrosis-market

**If You Have Any Special Requirements, Please Let Us Know And We Will Offer You The Report As You Want**

Strategic Points Covered in Table of Content of Cystic Fibrosis Market:

Chapter 1: Introduction, Definition, Specifications, Classification and Scope the Cystic Fibrosis Market

Chapter 2: Exclusive Summery like Industry chain structure, Manufacturer cost structure, suppliers, etc

Chapter 3: Displays Trends, Drivers and Challenges of the Cystic Fibrosis Market

Chapter 4: By the study of SWOT analysis it displays sales analysis, investment analysis, market analysis, etc

Chapter 5: It evaluates the market by segments, by countries and by manufacturers with revenue, share and sales by key countries in these various regions.

Chapter 6: Evaluate the leading manufacturers of the Global Cystic Fibrosis Market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile

Chapter 7: Cystic Fibrosis Research Findings and Conclusion, Appendix, system and information source

Reasons to buy this report:

• This report offers a broad and concise analysis of the Double Cystic Fibrosis market using a robust research methodology and focusing on various data available for the historical period of past five years.

• To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

• Assess the production processes, major issues, and solutions to mitigate the development risk.

• To understand the most affecting driving and restraining forces in the market and its impact in the global market.

• Learn about the market strategies that are being adopted by leading respective organizations.

• To understand the future outlook and prospects for the market.

Access Full Report information with TOC, here@ https://www.databridgemarketresearch.com/reports/global-cystic-fibrosis-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

Browse Related Reports@

Nanomedicine for Drug Delivery Market

Rathke's Cleft Cyst Market

Johnson Neuroectodermal Syndrome Market

[cool-akashy-maximize]

Global Leukemia Therapeutics Market : Industry Analysis and Forecast (2019-2027)

Global Leukemia Therapeutics Market was valued at US$ 11.32 Bn in 2019 and is expected to reach US$ 19.2 Bn by 2027, at a CAGR of 7.84 % during the forecast period.

The report includes an analysis of the impact of COVID-19 lockdown on the revenue of market leaders, followers, and disruptors. Since the lockdown was implemented differently in various regions and countries; the impact of the same is also seen differently by regions and segments. The report has covered the current short-term and long-term impact on the market, and it would help the decision-makers to prepare the outline and strategies for companies by region. Global Leukemia Therapeutics MarketGlobal Leukemia Therapeutics Market Dynamics:

Increased prevalence of cancer especially blood cancer across the globe is leading to increasing demand for effective treatments, which is the driving factor for market growth. Increase in expenditure on the development of novel treatment and developing health infrastructure is further driving the market growth. Additionally, the growth in survival rate and minimum side effects of novel treatment such as stem cell therapy, bone marrow transplant has open new avenues for market growth. Also, increased exposer to chemical mutation, changing dietary habits, and the living style of the population is further pushing the market growth.

The lack of early diagnosis and awareness among the public are leading challenges in the market for leukemia therapeutics. Furthermore, redefining the drug lifecycle roadmap is a major challenge for drug innovators. However, breakthrough therapy designations and accelerated approvals granted by regulatory bodies like the FDA would offer lucrative market opportunities for the drug innovators. Segment Analysis of the Global Leukemia Therapeutics Market:

Based on treatment type, chemotherapy led the segment in 2019. Because of its ability to kill cancerous cells or inhibiting their proliferation and maintain a normal level of lymphocytes of chemotherapy, is driving the market growth. Similarly, the increased survival rate of the patients treated with chemotherapy is again fueling its demand.

On the basis of the type of leukemia, acute lymphocytic leukemia is dominating the segment and has accounted for maximum market share. Owing to the rising condition of cancerous cells, acute leukemia is driving the segment growth. Increasing smoking habits, exposure to chemicals, radiation, and cases with other blood-related disorders are again driving the segment growth. Regional Insights of the Global Leukemia Therapeutics Market:

In terms of region, North America followed by Europe dominates the global leukemia therapeutics market owing to the growing incidence of cancer and increasing aging population. The APAC is expected to show a high growth rate because of the increasing incidence of cancer. China and India are expected to be the fastest-growing leukemia markets in the Asia Pacific region. Some of the key driving forces for the leukemia therapeutic market in emerging economies are increasing R&D investment, a large pool of patients, and growing government funding.

Key developments in leukemia therapeutics market: In February 2018, Sanofi announced to discard the mid-stage exertion on ALL therapy for the anti-CD38 antibody isatuximab. Also, Erytech Pharma broadened the scope of eryaspase (GRASPA) growth for solid tumors further clinical studies in triple-negative breast cancer.

The objective of the report is to present a comprehensive assessment of the market and contain thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding Global Leukemia Therapeutics Market dynamics, structure by identifying and analyzing the market segments and project the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence. Scope of the Global Leukemia Therapeutics Market Report:

Global Leukemia Therapeutics Market, by Type of Leukemia

• Chronic Myeloid Leukemia • Chronic Lymphocytic Leukemia • Acute Lymphocytic Leukemia • Acute Myeloid Leukemia

Global Leukemia Therapeutics Market, by Treatment Type

• Targeted Drugs & Immunotherapy • Chemotherapy

Global Leukemia Therapeutics Market, by Molecule Type

• Small Molecules • Biologics

Global Leukemia Therapeutics Market, by Mode of Administration

• Oral Mode • Injectable Mode

Global Leukemia Therapeutics Market, by Gender

• Males • Females

Global Leukemia Therapeutics Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America Key Players Operating in the Global Leukemia Therapeutics Market:

• Novartis AG • AbbVie • Bristol-Myers Squibb • Hoffmann-La Roche • Sanofi • Pfizer • Amgen • Gilead Sciences • Takeda • Celgene • AbARIAD Pharmaceuticals, Inc. • F. Hoffmann-La Roche Ltd. • Genzyme Corporation • GlaxoSmithKline plc. • Teva Pharmaceuticals • Allergan, • AstraZeneca, • F. Hoffmann-La Roche Ltd, • Pfizer Inc., • Merck KGaA, Merck & Co., Inc.,

For More Information Visit @: This Report Is Submitted By : Maximize Market Research Company Customization of the report: Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research: Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

[colorfulnerddaze]

Liver Cirrhosis Treatment Market- Global Industry Analysis By Development, Size, Share 2027

The Global Liver Cirrhosis Treatment Market in Terms of Revenue Was Worth of USD 4.27 Billion in 2020 and is expected to reach USD 8.17 Billion in 2027, growing at a CAGR of 9.97% from 2021 to 2027.

The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Liver Cirrhosis Treatment Market. It includes Porter’s Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Liver Cirrhosis Treatment Market. We have provided deep analysis of the vendor landscape to give you a complete picture of current and future competitive scenarios of the global Liver Cirrhosis Treatment market. Our analysts use the latest primary and secondary research techniques and tools to prepare comprehensive and accurate market research reports.

Get Sample Copy of this Premium Report: https://brandessenceresearch.com/requestSample/PostId/1466

Top Key players in the report:

Gilead     Sciences, Inc.

Shionogi & Co., Ltd.

Sanofi

British Biologicals

Hoffmann-La Roche Ltd.

Merck & Co., Inc.

Others

The final report will add the analysis of the Impact of Covid-19 in this report Liver Cirrhosis Treatment Market

Liver Cirrhosis Treatment Market reports offers important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion, acquisition, and new product launch as well as analyzing and understanding the market trends.

The growing aging population, excessive alcohol consumptions, and increasing prevalence of liver diseases are the major factors driving the market growth. In the recent years, the changing lifestyle is a major factor increasing the alcohol consumption. For example; According to the 2019 National Survey on Drug Use and Health; 14.1 million adults ages 18 and older had alcohol use disorder. This includes 8.9 million men and 5.2 million women. Additionally, they estimated 95,000 people die from alcohol-related causes annually. 

Top Segmentation Analysis:  

Global Liver Cirrhosis Treatment Market:

By Treatment

Antibiotics

Immunosuppressants

Others

Global Liver Cirrhosis Treatment Market:

By End User

Hospitals and Clinics

Research and Academic Institutes

Others

Geographically, this report split global into several key Regions, revenue (Million USD) The geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Post-Consumer Liver Cirrhosis Treatment Market.

Key Benefits for Liver Cirrhosis Treatment Market Reports

The analysis provides an exhaustive investigation of the global Post-Consumer Liver Cirrhosis Treatment market together with the future projections to assess the investment feasibility. Furthermore, the report includes both quantitative and qualitative analyses of the Post-Consumer Liver Cirrhosis Treatment market throughout the forecast period. The report also comprehends business opportunities and scope for expansion. Besides this, it provides insights into market threats or barriers and the impact of regulatory framework to give an executive-level blueprint the Post-Consumer Liver Cirrhosis Treatment market. This is done with an aim of helping companies in strategizing their decisions in a better way and finally attains their business goals.

Each segment of the global Liver Cirrhosis Treatment market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Liver Cirrhosis Treatment market through leading segments. The regional study of the global Liver Cirrhosis Treatment market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global Liver Cirrhosis Treatment market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Global Liver Cirrhosis Treatment Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global Liver Cirrhosis Treatment market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global Liver Cirrhosis Treatment market.

The Middle East and Africa (GCC Countries and Egypt)

North America (the United States, Mexico, and Canada)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France,     etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan,     Philippines, Korea, Thailand, India, Indonesia, and Australia)

Global Liver Cirrhosis Treatment Market: Competitive Rivalry

The chapter on company profiles studies the various companies operating in the global Liver Cirrhosis Treatment market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Liver Cirrhosis Treatment market participants in the past few years to remain ahead of the competition.

Report Highlights

Comprehensive pricing analysis on the basis of product,     application, and regional segments

The detailed assessment of the vendor landscape and     leading companies to help understand the level of competition in the     global Liver Cirrhosis Treatment     market

Deep insights about regulatory and investment scenarios     of the global Liver Cirrhosis     Treatment market

Analysis of market effect factors and their impact on     the forecast and outlook of the global Liver Cirrhosis Treatment market

A roadmap of growth opportunities available in the     global Liver Cirrhosis Treatment     market with the identification of key factors

The exhaustive analysis of various trends of the global     Liver Cirrhosis Treatment     market to help identify market developments

Get Methodology: https://brandessenceresearch.com/requestMethodology/PostId/1466

Table of Contents

Report Overview: It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, Liver Cirrhosis Treatment market segments by application, study objectives, and years considered.

Global Growth Trends: There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis.

Liver Cirrhosis Treatment Market Share by Manufacturer: Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.

Market Size by Type: It includes analysis of price, production value market share, and production market share by type.

Market Size by Application: This section includes Liver Cirrhosis Treatment market consumption analysis by application.

Profiles of Manufacturers: Here, leading players of the global Liver Cirrhosis Treatment market are studied based on sales area, key products, gross margin, revenue, price, and production.

Liver Cirrhosis Treatment Market Value Chain and Sales Channel Analysis: It includes customer, distributor, Liver Cirrhosis Treatment market value chain, and sales channel analysis.

Market Forecast – Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Get Full Report: https://brandessenceresearch.com/healthcare/liver-cirrhosis-treatment-market

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

[dpiresearchofficial]

The global 50 blockbuster drugs market size is estimated to reach a value of US$ 292 billion by 2025. ‘Global Blockbuster Drugs Market 2015 – 2025: Top 50 Drugs Analysis, Deal Trends, Players and Forecasts’ presents an in-depth assessment of the global blockbuster drugs market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for global blockbuster drugs market. The report includes historic data from 2015 to 2017 and forecasts until 2025. The report contains a granular analysis of the present industry situations, market demands, reveals facts on the market size, revenues and provides forecasts through 2025. The report provides clear insight into current and future developments of the global blockbuster drugs market. The report explores detailed analysis of top 50 drugs market assessment globally from 2015 to 2017 and forecasts to 2025. The report also details the latest information about the global research & development spend by pharma & biotech companies Additionally, the report includes assessment of most valuable drugs research and development projects insights by phase and market value. Key trends in terms of collaboration, merger & acquisition, partnerships and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the global blockbuster drugs market. The report concludes with the profiles of major players in the global blockbuster drugs market. The key market players are evaluated on various parameters such as business overview and recent development. The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are: 1) AbbVie 2) Celgene 3) Gilead Science 4) Merck 5) Roche 6) Bristol–Myers Squibb 7) Pfizer 8) Johnson & Johnson 9) Amgen 10) Biogen 11) Bayer 12) Regeneron Pharmaceuticals 13) Novo Nordisk 14) Allergan 15) Alexion Pharmaceuticals 16) GlaxoSmithKline 17) Novartis 18) Eli Lilly and Company 19) Astrazeneca 20) Incyte Corporation 21) Boehringer Ingelheim 22) Astellas Pharma Top 50 Blockbuster Drugs Covered Under This Report Are: 1) Humira 2) Imbruvica 3) Revlimid 4) Genvoya 5) Truvada 6) Harvoni 7) Epclusa 8) Keytruda 9) Januvia/Janumet 10) Herceptin 11) Avastin 12) MabThera/Rituxan 13) Perjeta 14) Opdivo 15) Eliquis 16) Orencia 17) Sprycel 18) Lyrica 19) Ibrance 20) Simponi 21) Stelara 22) Zytiga 23) Invega Sustenna 24) Xarelto 25) Enbrel 26) Tagrisso 27) Tecfidera 28) Eylea 29) Victoza 30) Botox 31) Soliris 32) Triumeq 33) Seretide/Advair 34) Gilenya 35) Cosentyx 36) Trulicity 37) Cialis 38) Humalog 39) Symbicort 40) Zepatier 41) Pomalyst/Imnovid 42) Darzalex 43) Prolia/Xgeva 44) Ocrevus 45) Xtandi 46) Tivicay 47) Jakafi/Jakavi 48) Jardiance 49) Trajenta/Jentadueto 50) Relvar/Breo Ellipta The Latest Industry Data Included in this Report: Global Top 50 Blockbuster Drugs Market Size & Analysis (2015 – 2025) Global Top 50 Blockbuster Drugs Market Share & Y–o–Y Growth (%), 2015 – 2025 Global Top 50 Blockbuster Drugs Market Assessment & Opportunity, (2015 – 2025) Most Valuable Drugs Research and Development (R&D) Projects Insights by Phase and Market Value Global Research & Development (R&D) Spend by Pharma & Biotech Companies (2015 – 2025) Major Deals (Mergers, Acquisitions, Key Agreements, Partnerships & Collaborations) Key Market Drivers and Inhibitors of the Global Blockbuster Drugs Market Major Companies Analysis The Answers to the Following Key Questions can be found in the Report: What is the size of the global top 50 blockbuster drugs market during 2015 -2025? What will be the revenue generated by each drug during the forecast period? Which major drugs provides the highest market share? How are the overall market and major drugs growing? What are the key drivers and inhibitors in the current market? What will be the impact of drivers and inhibitors in the future? How is the market predicted to develop in the future? Who are the key players in this market space?

[myoliver123stuff]

Neglected Tropical Disease Treatments Market– Insights on Emerging Scope 2021

The global market for neglected tropical diseases should reach $2.6 billion by 2021 from $1.4 billion in 2016 at a compound annual growth rate (CAGR) of 14.1%, from 2016 to 2021.

Report Scope:

The report focuses on newer drugs and innovations in chemical compounds, vaccines and biologicals recently launched or in development. Specifically excluded from the scope of research are vector or mosquito control approaches, strategies and products; drugs used for symptomatic treatment and not for the elimination of the virus from the host; and details on manufacturers and suppliers of nonbranded generics.

Get More Information sample: https://www.trendsmarketresearch.com/report/sample/11821

Products used for diagnosis as well as PCR techniques, kits and testing facilities are also excluded from the report.

BCC Research has categorized the markets based on regions defined by the WHO since it is the primary organization mapping disease prevalence, assisting with access to medicine and enabling partnerships. Regions include Africa, Americas, South-East Asia, Europe, Eastern Mediterranean and Western Pacific. These cover all the WHO participating countries which are described in detail in the subsequent section.

Report Includes:

– An overview of the global markets for tropical disease treatments. – Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021. – A look at the total addressable market, an indication of the number of people affected, and the current shares of key marketed therapies. – Representations of market shares by geography, company, and future outlook. – Insight on some of the newer drug candidates, clinical trials, and their end points. – Analyses of factors such as increases in resistance of vectors to common insecticides, increases in rapid diagnostic techniques, and no established treatment for newer conditions like Zika. – Profiles of major players in the industry.

Report Summary

Neglected tropical diseases are a significant cause of death and morbidity among affected communities around the world. In 2015, the total addressable market for the diseases discussed in this report was $1.4 billion and is expected to grow at a compound annual growth rate (CAGR) of 14.1% to over $2.6 billion by 2021. The global market for malaria treatments in 2015 was about $440.3 million (including preventive medicine for pregnant women and children under five years of age in Africa) and is expected to reach $757.9 million by 2021. In 2015, the global market for leishmaniasis treatments was $33.8 million although, as the disease has a focal distribution, this total does not reflect the extent of visceral leishmaniasis in affected communities.

Request for Discount : https://www.trendsmarketresearch.com/report/discount/11821

The 2015 market value for schistosomiasis was $52.5 million, out of which preventive chemotherapy was about $18 million. Coverage of preventive chemotherapy by the WHO authorities, according to our estimates is expected to grow to $46 million by 2021 for a market that, according to the demand will by then be valued at $55.8 million. Our projection of the market for Lymphatic Filariasis, for the year 2021, comes to $8,500. This falls in line with WHO’s roadmap in which the global market for preventive chemotherapy will be reduced to near negligible with a very limited market for drugs. A challenge in estimating the market size of such diseases is underreporting due to the large number of cases that go undetected or misdiagnosed.

Vaccines are making an entry into the market with recently approved GlaxoSmithKline’s Mosquirix for malaria and Sanofi’s Dengvaxia for dengue. Both near-term and long-term launches are also expected for other indications such as Zika and leishmaniasis. The projected 2017 market size for malaria vaccines is about $170 million. In 2015, the total addressable (demand) markets for dengue and Zika vaccines was $246.2 and $36.3 million but are expected to increase to about $1.3 billion and $132 million, respectively, by 2021. This surge is based on the understanding that the vaccines will be part of a routine immunization program in key markets. Innovation and launches in vaccines will continue to drive the market.

Other incentives like the U.S. FDA’s Priority Review Voucher scheme as well as public-private partnerships via platforms like DNDi and funding from organizations and governments are expected to boost research. Advances are much needed since most of the existing treatments for many tropical diseases are decades old, often unaffordable and difficult to administer. Another trend that will be driving research is the increase in parasite resistance.

Key organizations that will influence the market and have been profiled in this report include: GlaxoSmithKline, Drugs for Neglected Diseases Initiative, Medicines for Malaria Venture, Merck, Sabin Vaccine Institute, Anacor Pharmaceuticals (now Pfizer), Sanofi-Aventis and Sanofi Pasteur, Takeda, Eisai, PATH Malaria Vaccine Initiative, Novartis, Instituto Butantan, Johnson & Johnson, Bayer and Gilead Sciences.

The market has long been neglected because these diseases primarily affect marginalized communities which makes treatment expensive and diagnosis difficult. However, the recent Ebola and Zika outbreaks have highlighted the threat and the unpreparedness of the authorities.

Request For Report Analysis: https://www.trendsmarketresearch.com/report/analysis/BCC/global-markets-for-neglected-tropical-disease-treatments-market

[van-awesome]

The Handmaid’s Tale isn’t chilling because it gives us a precise roadmap to real-world tyranny. It’s scary because it suggests that no matter how many decades of progress we make, Gilead will never be more than a few steps behind us. And if we ever stop watching for it, it’s ready to drag us down.

Adi Robertson, The Verge

The Handmaid’s Tale is a chilling expansion on Margaret Atwood’s novel

[duaneodavila]

The Drug Patent Two-Step

It is well-known that patents are more valuable in certain industries than others. Whether it is because the eligibility of certain technology for patenting is in constant question — software, meet Alice — or because of the presence of standard-essential patents with their resultant FRAND obligations, in certain industries any given patent may not be very valuable. In contrast, industries like pharmaceuticals and medical devices, where a small set of patents can cover a blockbuster drug or device, are often thought of as having valuable patents. But recent developments have helped call this orthodoxy into question, particularly with respect to drug patents.

A quick review of the recent patent news lends further support to the idea that pharmaceutical companies face challenges on the patent front. Knowledgeable observers have been aware of this phenomenon for years, with the idea that drug patents are vulnerable and overvalued fueled by Kyle Bass’s quixotic IPR-driven stock-shorting campaign — and confirmed by the earnest lobbying of the drug industry to exempt itself from the IPR regime completely. At the same time, the past few years have seen a number of high-profile competitor cases in the drug industry, with blockbuster offerings from one company attacked by a patent holder hoping for a royalty. Industry giant Merck, for example, has found itself in the role of both predator and prey in this respect, with its assaults against Gilead’s hepatitis C franchise balanced by its defensive efforts against Bristol Myers Squibb’s attacks on its own blockbuster Keytruda anti-cancer therapy.

In short, we have drug companies that have been forced into a very dangerous corner. On the one hand, they can find themselves arguing that their patents are valid and valuable, particularly when defending themselves in an IPR or ANDA litigation. At the very same time, however, that same drug company may be arguing that a competitor’s patents — directed at the very same drug they are making money on, and conceivably have their own patents on — are no good. The message this drug patent two-step sends to investors and the general public is not a very defensible one, namely that, “Our patents are all good, but our competitor’s patents stink. Even though our competitor is asserting patents that conceivably cover our blockbuster drugs, and our patents may overlap with theirs on that same technology.” Yes, no drug company spokesman has laid it out that way. But any honest analysis of how drug companies behave will reveal that the behavior underlying that message is not uncommon.

Compounding the difficulty of walking such a fine line is the growing body of evidence that many drug patents are really not that strong to begin with — even though they may be valuable by dint of the revenues of the drug they “protect.” Two examples from recent weeks are illustrative. First, the biggest royalty verdict in patent history — Merck’s trial victory over Gilead with respect to royalties from two of the biggest drugs of all time, hepatitis C cures Harvoni and Solvadi — was thrown out on a post-trial JMOL invalidity filing. In that decision, the court found the asserted patent invalid for lack of enablement — which in layman’s terms is the equivalent of saying that a math textbook doesn’t actually do the job of teaching the reader how to solve geometry problems. Put another way, a patent that commanded a multi-billion dollar jury verdict — as good a sign of value as you would ever expect to get — was thrown out as invalid because it amounted to little more than a roadmap for years of additional experimentation, rather than a roadmap for making the drugs that we expect to see in exchange for the limited monopoly conferred by a patent.

Yet Merck was not the only pharmaceutical giant to face an adverse decision recently. In another long-anticipated ruling, the PTAB found that Allergan’s attempt to end run the IPR process by assigning patents covering its blockbuster eye treatment Restasis to an Indian tribe would not result in the termination of the nearly-final IPRs. While the specifics of the decision are interesting, and raise important questions about the PTAB’s authority to decide issues other than patent validity, there is no doubt that the result is a blow to Allergan’s attempts to shield its Restasis patents from an ultimate invalidity finding — especially since the district court presiding over the corresponding ANDA case involving those patents had already found them invalid. Whether the generic challenger is heartened enough by this latest ruling to launch at-risk (pending Allergan’s inevitable Federal Circuit appeals) is an open question. What is clear, however, is that drug companies like Allergan are willing to try everything to keep their valuable patents alive. Despite those efforts, even the most creative (desperate?) strategies will not go far when the quality of the underlying patents are not commensurate with their purported value.

Ultimately, these recent decisions illustrate how challenging the current patent environment is for pharmaceutical companies. At the same time, the increased focus on aligning patent quality and value — driven in large part by IPRs as a first-line defense to charges of patent infringement – has made life more difficult for patent owners of all stripes. What we can expect to see is branded pharmaceutical companies continuing to chafe at having their patents susceptible to IPRs, while continuing to look for opportunities to use their patents as a potential means of getting royalties from competitors fortunate enough to have a blockbuster drug on their hands. In short, the drug patent two-step will continue, as long as the existing legal jukebox keeps playing.

Final Note: We are entering a busy season of IP-focused conferences. In my experience some of the best IP-related conferences are put on by organizations in the IP media-space, such as Managing Intellectual Property (MIP). For those interested, MIP’s US Patent Forum 2018 is open for registration here. The event is free to attend for in-house counsel, and the agenda looks ambitious and interesting. If you are planning on attending the event as I am, please reach out as I would be keen on meeting readers of this column in-person.

Please feel free to send comments or questions to me at gkroub@kskiplaw.com or via Twitter: @gkroub. Any topic suggestions or thoughts are most welcome.

Gaston Kroub lives in Brooklyn and is a founding partner of Kroub, Silbersher & Kolmykov PLLC, an intellectual property litigation boutique, and Markman Advisors LLC, a leading consultancy on patent issues for the investment community. Gaston’s practice focuses on intellectual property litigation and related counseling, with a strong focus on patent matters. You can reach him at gkroub@kskiplaw.com or follow him on Twitter: @gkroub.

The Drug Patent Two-Step republished via Above the Law

[ketan-wagh121-blog]

Covid-19 Impact on Blockbuster Drugs Market: Global Industry Analysis and Opportunity Assessment, 2019 – 2025

Global Blockbuster Drugs Industry

According to the latest report added to the online repository of Wise Guys Reports (WGR) the Global Blockbuster Drugs market has witnessed an unprecedented rise and the extrapolated growth is expected to touch $292 billion by 2025 registering a more than average CAGR.

Try Sample of Global Blockbuster Drugs Market @ https://www.wiseguyreports.com/sample-request/3602067-global-blockbuster-drugs-market-2015-2025-top-50

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Medications that generate more than $1 billion in revenue in a year for their respective pharmaceutical companies are termed as Blockbuster drugs. Most of the pharmaceutical companies register profit aided by the right collaboration of time, work and effort put in developing these new drugs which is indispensable to their success. Thus if a drug is elevated to the level of blockbuster drug then it becomes a matter of great achievement and accomplishment for the pharmaceutical companies and their investors. Although due to the patent laws the live span of the success is usually short-lived for these blockbuster drugs. This puts doubt and unreliability in the revenue generated by the pharmaceuticals through the production of new drugs.

As of 2005 the global pharmaceutical market was valued at $600 billion out of which 60% of the $245 billion in earnings of top 10 pharmaceuticals was attributed to successful medication.  But most of the currently high revenue generating drugs will face patent expiration in the coming few years which could result in diminishing sales figures. The reason of decreasing number of blockbuster drugs in the market over the years can be divided into two major reasons. Firstly stringent regulations and guidelines have resulted into fewer numbers of drugs qualifying for US FDA approval. Secondly, negligence on part of the pharmaceutical companies in their research and development sector resulting into poor drugs that is not able to meet US FDA recommended standards. However according to the Pharmaceutical Research and Manufacturers of America more money is funnelled into R&D with a 65% increase in budget spent on research and development in 2006 as compared to 2000. This makes pharmaceutical sector as the most research oriented sector in US.

The report provides insight into global blockbuster drugs market dynamics and opportunities by laying the future roadmap and focusing on the competitive landscape and major trends. Most current market study along with in-depth analysis is included as part of the report to offer better and comprehensive view.

Global Blockbuster Drugs Market: Major Players

Using business overview and recent developmental progress as the pivotal points the major players of the market is recognized.

The major companies in terms of generating revenue are AbbVie, Bayer, Regeneron Pharmaceuticals, Novo Nordisk, Allergan, Celgene, Gilead Science, Astrazeneca, Incyte Corporation Merck, Roche, Bristol–Myers Squibb, Pfizer, Johnson & Johnson, Amgen, Biogen,, Alexion Pharmaceuticals, GlaxoSmithKline, Novartis, Eli Lilly and Company, Boehringer Ingelheim & Astellas Pharma.

Global Blockbuster Drugs Market: Top 50 Drugs

The top 50 Blockbuster drugs in the market are Humira, Jakafi,Jakavi, Jardiance, Trajenta , Jentadueto & Relvar, Imbruvica, Revlimid, Genvoya, Truvada, Harvoni, Epclusa, Keytruda, Januvia,Janumet, Herceptin, Triumeq, Seretide,Advair, Gilenya, Cosentyx, Trulicity, Cialis, Humalog, Symbicort, Zepatier, Avastin, MabThera,Rituxan, Perjeta, Opdivo, Eliquis, Orencia, Sprycel, Lyrica, Ibrance, Simponi, Stelara, Zytiga, Invega Sustenna, Xarelto, Enbrel, Tagrisso, Tecfidera, Eylea, Victoza, Botox, Soliris, Pomalyst,Imnovid, Darzalex, Prolia,Xgeva, Ocrevus, Xtandi, Tivicay, Breo Ellipta.

For Detailed Reading Please visit WiseGuy Reports @  https://www.wiseguyreports.com/reports/3602067-global-blockbuster-drugs-market-2015-2025-top-50

For more information or any query mail at sales@wiseguyreports.com

About Us Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us: Norah Trent +1 646 845 9349 / +44 208 133 9349

NOTE : Our team is studying Covid-19 and its impact on various industry verticals and wherever required we will be considering Covid-19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

[mildredjizquierdo]

4 predictions for the next phase of the COVID-19 pandemic

Peering into the future of COVID-19

Introduction

COVID-19’s impact on the United States and its healthcare system is unprecedented.  In this piece, I make four predictions for what the next phase will bring. Each has important strategic implications for healthcare companies and investors.

Here’s what I expect:

Treatment, not testing will be key to reopening the economy

Hybridization (virtual/in-person mix) will be the new reality

Public health post-COVID-19 will be like security post-9/11

The federal government will grow even more powerful relative to everything else

Treatment, not testing will be key to reopening the economy

It is accepted wisdom among public health experts and many others that the widespread availability of COVID-19 testing is a necessary condition to reopen the economy. It says so on the roadmaps of California, Massachusetts, the federal government, and many companies and institutions. It makes great sense: once we can see the problem clearly we can prevent infections from spreading. Other countries that are reopening –like Germany and Singapore—make extensive use of testing and contact tracing. This, we’re told, is the way things will be until a vaccine is introduced in a year or so.

Here’s the problem: progress on ramping up testing has been slow, even in Massachusetts where I assumed it would go fast. Despite lots of announcements of new capacity coming online I haven’t seen anything that makes me think there will be a breakthrough. Consider, also that effective testing for COVID-19 can’t be a one-time phenomenon. People will need to be tested over and over.

Meanwhile, with the worldwide deluge of patients, doctors are figuring out how to treat them. We might not have a vaccine in a year –or ever (unfortunately), but treatments are improving now, through experimentation, physician insight, and good luck. There is early promise from Gilead’s remdesivir; other drugs will be useful, too. But it’s not just drugs, it’s also non-drug adjustments such as how to optimize use of mechanical ventilation for these patients and even when to turn them onto their stomachs. As another example, I received firsthand reports from frontline Italian physicians who hypothesize that the coronavirus attacks the cardiovascular system first, and that is where to focus to address the root cause in a straightforward way. These are just things I’ve been privy to; certainly there are thousands of other investigations going on around the world. Some will work, and soon. These innovations can be additive or multiplicative, even if they’re not a miracle cure.

Bottom line, I think it’s likely that COVID-19 will become a manageable disease within a few months or even a few weeks, and that’s what will enable us to start to go back to work and school and to start flying again with an acceptable level of risk. For better or worse, it’s also more consistent with how the American healthcare system works: treat the sick.

It would be so much better to have ample testing in place before trying to reopen. Until we get there the US will suffer from higher disease burden, greater cost, higher inequities, and more skittishness about public gatherings compared to other countries. Yet as a whole we will figure out how to make do without the testing capacity that everyone wants.

 Hybridization (virtual/in-person mix) will be the new reality

 When COVID-19 hit, telemedicine made more progress in one week than it had in the past 10 years. Suddenly patients were scared to come to the office or hospital (and doctors/nurses/staff were afraid of the patients), reimbursement with in-person visits was equalized, and cross-state licensing restrictions were eased. People are getting accustomed to online meetings, online socializing, online schooling, and online shopping. Some of it –like convenience, immediacy—they like. Other parts –such as the difficulty building new, trusting relationships and absence of physical contact, and difficulty interacting with groups or teams—they don’t.

The pandemic will be with us for a while, which means people will have plenty of time to get used to being remote, understand better how to make it work, and won’t always default to the old ways. This is true even for some older Americans who thought they’d be able to ride out their careers or lives without jumping into the digital waters.

There has been a gradual shift to online over the past couple of decades, but the pandemic changes things. Now, we realize that we may have to suddenly revert to a remote world at any time, so we had better be ready for it. Social distancing is likely to be required to some degree over the next couple years, which means offices, factories, schools and entertainment venues won’t be able to return to their previous density. We can expect to see a rotation of remote and in-person staff and students –instead of total shutdowns. And kids may not like it, but there will be no excuse for another snow day!

Health status and age will play important roles in how hybridization is realized. Older people and those with conditions making them vulnerable may find that they have to spend more time in the digital world than their younger and healthier peers, because it’s not safe for them to show up in person. Ageism and discrimination against people with disabilities is already a major problem. It will become much more so in a COVID-19 influenced economy, especially during a recession where the job market favors employers.

For healthcare delivery and clinical trials, it is likely that more routine interactions will be conducted online rather than the office, and that the home will become even more attractive for recovery, aging and research. Providers will make greater use of nurse practitioners and physician assistants as front-line representatives, for triage, follow up and care coordination. It’s more straightforward to standardize protocols and supervise staff in the digital realm, plus it’s cheaper. We will also see a rise in asynchronous interactions, which are often more effective and efficient than as live video call. With the right leadership, these changes can also facilitate an increase in value based and evidence based cared.

The current situation has very negative consequences for the health of people with chronic and even acute conditions, who are avoiding the doctor and hospital at all costs. Meanwhile, providers face financial ruin as patients stay away. It has to be addressed, and hybridization is the way to do it. 

Public health post-COVID-19 will be like security post-9/11

After 9/11, security came to the fore. Suddenly there was visible security at airports, in office buildings, and throughout public spaces. New physical and digital surveillance technologies and practices were introduced and there was massive hiring of security guards, analysts, etc.

Now that COVID-19 has struck, we can expect public health to be similarly elevated. It will become a pervasive part of our economy and society. Expect temperature –and maybe face mask and hand washing– checks at the office, school, and any public venue.  Contact tracers may call or visit our homes or scrutinize our cellphone records. Event managers and employers will need to hire a health team and devise a health/safety plan to prevent outbreaks and provide confidence.

New products and tools will be needed to sanitize surfaces, detect pathogens in the environment, and monitor outbreaks. Sick leave policies will need to be revised and enforced. New cultural norms will be established –for example on the wearing of masks, shaking hands, what personal space means. Mental health needs must also be recognized and addressed in the adult and pediatric populations.

It won’t be enough to pursue these approaches privately. Local, state, and federal agencies will have to invest in order to deploy a comprehensive strategy to protect and reassure the public.

The new public health approach will dovetail with existing post 9/11 security measures and infrastructure. For example, the Red/Orange/Yellow/Blue/Green threat level developed for terrorism is actually more suitable to viral dangers. There will also be opportunities to redefine and expand the corporate wellness industry, which at last will be able to demonstrate a robust return on investment.

Federal government will grow even more powerful relative to everything else

The federal response to the pandemic has been problematic. The US had time to prepare after observing China and Europe, but largely failed to do so. States complain that there’s been little federal response or coordination and that they have been left to fend for themselves. The underlying reasons and political elements can be debated elsewhere.

Somewhat paradoxically, the pandemic has strengthened the federal hand relative to others. Consider:

With interest rates near zero, the federal government is easily able to borrow $2+ Trillion for the CARES Act

The Federal Reserve has propped up the stock and bond market with its promise to buy essentially anything, including non-investment grade securities

States are facing huge drops in revenues thanks to the shutdown of the economy. They need to balance their budgets and don’t have the borrowing powers of the feds. They also have to beg the federal government for assistance with the current crisis

The completely unprecedented surge in unemployment is leading to dependency on programs such as SNAP and Medicaid that are primarily funded at the federal level

Many industries –think travel, tourism, restaurants—are essentially shut down and need a bailout to restart

Colleges and universities, are hamstrung by having to close their campuses -possibly through the fall semester as well—and the question of whether domestic and especially international students will return

The healthcare delivery system is suffering from a huge disruption as essentially all resources are diverted to COVID-19 or idled

The broad implications of this sudden swing will play out over time and will be affected by the November elections (assuming they occur on schedule). The pandemic really does place the country at a crossroads. The conditions are ripe for further dividing the nation along various fault lines (rural/urban, nationalist/globalist, etc.) or for bringing us together. We may also see blocs of states ally more formally to coordinate with one another and attempt to shift the balance of power. Meanwhile, it is notable that this federal power expansion, involvement in the economy and massive increase of borrowing are occurring under ostensibly conservative leadership.

One near-term result is that the country has jumped much closer to the left-wing policies of Bernie Sanders and Andrew Yang than would have seemed imaginable in February. Everyone will be covered for COVID-19, whether directly through their insurance plans or through federal subsidies to providers, and the $1200 stimulus checks with the president’s signature are like Yang’s Universal Basic Income.

Massive unemployment will shift millions of people to Medicaid, so we may have Medicaid for All rather than Medicare for All. (This is actually a better idea, in my view.) I think we’ll see the holdout states finally accept the Affordable Care Act’s Medicaid expansion now that their backs are to the wall. And I also expect the COVID-19 experience means the Supreme Court will decline to strike down the Affordable Care Act, even though that won’t be the explicit rationale.

Conclusion

The situation is fluid and each of these predictions is subject to change. But I wanted to get some thoughts down while they were fresh, with the goal of spurring conversation and debate. In addition, I hope that clients will find this thinking useful as they determine what to do next and make longer term strategic and investment plans.

—

By healthcare business consultant David E. Williams, president of Health Business Group.

The post 4 predictions for the next phase of the COVID-19 pandemic appeared first on Health Business Group.